ContraFect Corporation (CFRX)

Business: ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States.

IPO Date: 29-Jul-2014

Chairman, CEO & Pres: Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.

Chief Financial Officer: Mr. Michael Messinger CPA, CPA

Listing: NASDAQ: CFRX

Country: United States

Headquarters: Yonkers, NY

Website: https://www.contrafect.com

Market cap: $120.75 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-35.18 Mln

Cash: $42.28 Mln

Total Debt: $3.17 Mln

Insider's Holding: 4.87%

Liquidity: Low

52 Week range: $2.11 - 4.76

Shares outstanding: 39,332,700

10 Years Aggregate:

• CFO: $-249.24 Mln
• EBITDA: $-277.76 Mln
• Net Profit: $-241.15 Mln